

MMRRC Submission Question List

Question	Help
<i>Are you the strain's developer?</i>	The strain's developer is the principal investigator who funded & directed the strain's development
<i>Who should we contact with questions regarding this submission?</i>	Typical follow-up questions pertain to details on genotype, phenotype, how the model was developed, collaboration arrangements, etc. This is best answered by the strain's developer or a person who was directly involved in the strain's development
<i>Is your strain distributed by another repository or commercial entity?</i>	This does not pertain to availability in another researcher's laboratory. Availability in another repository does not automatically exclude your strain from submission to the MMRRC!
<i>Is your submission pre-authorized by the NIH for MMRRC acquisition?</i>	Pre-authorized submissions are for use by researchers who have a strain that has been pre-approved for transfer to the MMRRC by their NIH Program Officer. The donor will be asked to identify the sponsoring institute. Program Officers must receive approval from the MMRRC's DPCPSI Program Officer to pre-authorize strains.
<i>Is the development of the strain described in a publication?</i>	The publication should provide procedural details of how the strain was made. Please provide a PMID , PMCID , or simply cite a reference (i.e., Dough <i>et al.</i> , Science 123:56, 2018). If the publication is not planned or ready: optional upload of supportive material is possible and recommended (e.g., phenotype data, data confirming recombination of a floxed allele, data confirming cre recombinase activity, reporter confirmation (e.g., images demonstrating activity, etc.). All material submitted is strictly <u>confidential</u> and only for the purpose of extracting information on the strain's/line's development, genotype, and phenotype.
<i>How many different investigators requested this strain in the past year?</i>	<input type="radio"/> 0 <input type="radio"/> 1-5 <input type="radio"/> >5
<i>Briefly describe the phenotype of the strain</i>	How is your model phenotypically unique compared to other strains that involve the same gene? Example: <ul style="list-style-type: none"> • homozygous: animals emaciated, have stunted growth, muscle rigidity • heterozygous: normal
<i>Strain Name</i>	As used in your lab or as published – proper nomenclature is <u>not</u> required; an official name will be generated later Examples: <ul style="list-style-type: none"> • Ptrb1 knockout • Scn1a(V247L) knock-in • Tg(PDGFB-APP) • Ethanol withdrawal seizure
<i>Current genetic background</i>	Examples: <ul style="list-style-type: none"> • mixed - B6;129P1 • congenic - 129.Cg or B6.C (Please provide the generation number, i.e., N=?) • coisogenic – C57BL/6N or BALB/c • uncertain – STOCK

Question	Help
<i>The allele is...</i>	(1) Targeted: <input type="radio"/> Knockout (Null) <input type="radio"/> Knock-in <input type="radio"/> Conditional <input type="radio"/> Gene Trap <input type="radio"/> CRISPR, TALEN <input type="radio"/> Other, explain (2) Non-targeted: <input type="radio"/> Induced <input type="radio"/> Spontaneous <input type="radio"/> Selective Breeding <input type="radio"/> Gene Trap <input type="radio"/> Other, explain (3) Transgenic: <input type="radio"/> Random Insertion <input type="radio"/> Targeted Insertion (4) Other, explain
<i>Gene information, MGI ID or NCBI ID</i>	Please provide the Mouse Genome Informatics (MGI) ID number or Entrez Gene ID number
<i>Gene alteration, short description</i>	Examples: <ul style="list-style-type: none"> • Targeted substitution in the Abcd gene (mRNA RefSeq: NM_00004352.1), c.403C>T, p.Tyr34Ala • Conditional ready knockout of the Abdc gene by floxing exons 5 through 11 • ENU mutagenesis induced a C-to-A point mutation that replaces lysine 706 with a threonine (T706K) <p>Need assistance with this section? Let us contact you later! Click YES to skip to the next section. We will contact you within 2 business days. This information will be needed prior to review.</p>
<i>Additional alleles?</i>	Please provide the same level of detail in your description of the additional allele(s) as shown above
<i>Are there any other characteristics or special circumstances that you wish for the MMRRC acquisition committee to consider when reviewing your mouse strain?</i>	Optional: Noteworthy additional information about your strain not covered in earlier responses or situations that would require special attention (e.g., closure/relocation of a lab, impending loss of funding, etc.)
<i>Donor MTA</i>	https://www.mmrrc.org/mta/incoming_mta.pdf
<i>Terms & Conditions</i>	https://mmrrc.org/terms